July 25, 2017

Tata Consultancy Services recognised as leader in life sciences BPO services

Report cites Tata Consultancy Services’ strong business process capabilities, global footprint and strategic partnerships as key attributes

New York | Mumbai: Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS) a leading global IT services, consulting and business solutions organisation, has been recognised as a ‘Leader’ for life sciences BPO services by leading advisory and research firm, Everest group, in its report titled Life Sciences BPO – Service Provider Landscape with PEAK MatrixTM Assessment 2017.
 
The report highlighted TCS’s strong business process capabilities across the board, including end-to-end service capabilities in all business process services and value chain segments for Life Sciences, with focus on pharmacovigilance and drug discovery processes. In addition, TCS is recognised for its highly qualified consultant base, providing it an edge over competitors in drug discovery, and clinical and pharmacovigilance services, and a well-diversified client split across the globe.

Everest group analysed the capabilities of 13 service providers on the Everest group PEAK Matrix in the global life sciences sector. The PEAK Matrix is a composite framework that provides an objective, data-driven and comparative assessment of life sciences BPO service providers, which are then divided into three categories — Leaders, Major Contenders and Aspirants — based on market success and delivery capability.

“Clinical research organisations’ limited capability to meet changing technology demands has created opportunities for business process services players to expand their offerings, particularly in the drug discovery and clinical research arenas,” said Manu Aggarwal, practice director, Everest group. “TCS’s strength in the medical domain, derived from its robust pharmacovigilance and regulatory practice, has enabled it to expand its reach into the clinical side, and address changing enterprise buyer needs,” Mr Aggarwal added.

“Life Sciences customers today seek to accelerate drug discovery and achieve greater operational efficiency while combatting increasing regulation and data safety concerns. By leveraging our domain expertise augmented by process automation, TCS Life Sciences is enabling customers to re-imagine their business across the life sciences value chain,” said Debashis Ghosh, president, life sciences, healthcare, government and energy business group, TCS. “With our consistent focus on digital solutions and development of next-gen platforms, we continue to add value to our customers,” added Mr Ghosh.